Escherichia coli
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA780210 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The study aimed to characterize plasmids mediating carbepenem resistance in Klebsiella pneumoniae in Pretoria, South Africa. We analysed 56 K. pneumoniae isolates collected from academic hospital around Pretoria. Based on phenotypic and molecular results of these isolates, 6 representative isolates were chosen for further analysis using long reads sequencing platform. We observed multidrug resistant phenotype in all these isolates, including resistance to aminoglycosides, tetracycline, phenicol, fosfomycin, floroquinolones, and beta-lactams antibiotics. The blaOXA-48/181 and blaNDM-1/7 were manily the plasmid-mediated carbapenemases responsible for carbapenem resistance in the K. pneumoniae isolates in these academic hospitals. These carbapenemase genes were mainly associated with plasmid replicon groups IncF, IncL/M, IncA/C, and IncX3. This study showed plasmid-mediated carbapenemase spread of blaOXA and blaNDM genes mediated by conjugative plasmids in Pretoria hospitals.
2019-10-17 | GSE138949 | GEO
Project description:The emergence of polymyxin resistance in carbapenem-resistant and extended-spectrum -lactamase (ESBL)-producing bacteria is a critical threat to human health, and new treatment strategies are urgently required. Here, we investigated the ability of the safe-for-human use ionophore PBT2 to restore antibiotic sensitivity in polymyxin-resistant, ESBL-producing, carbapenem-resistant Gram-negative human pathogens. PBT2 was observed to resensitize Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa to last-resort polymyxin class antibiotics, including the less-toxic next-generation polymyxin derivative, FADDI-287. We were unable to select for mutants resistant to PBT2 + FADDI-287 in polymyxin resistant E. coli containing a plasmid-borne mcr-1 gene or K. pneumoniae carrying a chromosomal mgrB mutation. Using a highly invasive K. pneumoniae strain engineered for polymyxin resistance through mgrB mutation, we successfully demonstrated the efficacy of PBT2 + FADDI-287 in vivo for the treatment of Gram-negative sepsis. These data present a new treatment modality to break antibiotic resistance in high priority polymyxin-resistant Gram-negative pathogens.
2020-07-01 | GSE153553 | GEO
Project description:The emergence of colistin resistance in carbapenem-resistant and extended-spectrum ß-lactamase (ESBL)-producing bacteria is a significant threat to human health, and new treatment strategies are urgently required. Here we investigated the ability of the safe-for-human use ionophore PBT2 to restore antibiotic sensitivity in several polymyxin-resistant, ESBL-producing, carbapenem resistant Gram-negative human pathogens. PBT2 was observed to resensitize Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa to last-resort polymyxin class antibiotics, including a ‘next generation’ polymyxin derivative, FADDI-287. To gain additional insight into the potential mechanism of action of PBT2, we analyzed the transcriptome of K. pneumoniae and E. coli in the presence of sub-inhibitory concentrations of PBT2. Treatment with PBT2 was associated with multiple stress responses in both K. pneumoniae and E. coli. Significant changes in the transcription of transition metal ion homeostasis genes were observed in both strains.
2019-06-13 | GSE132637 | GEO
Project description:Novel IncFII plasmid harbouring blaNDM-4 in a carbapenem-resistant Escherichia coli of pig origin, Italy
| PRJEB38506 | ENA
Project description:This project is about the proteomic and phosphoproteomic analyses of phage JSS1 or JSS1Δ004 infected Salmonella strains. AD032TQ is proteomes of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AD032TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AE065TQ is proteomes of phage JSS1 or JSS1Δ004 infected CX1, a S. enterica serovar Cerro 87 dndFGH deficient strain, harboring a plasmid expressing DndFGH from Escherichia coli B7A. AE065TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected CX1 harboring a plasmid expressing DndFGH from E. coli B7A.
2024-10-04 | PXD056211 | Pride
Project description:This project is about the proteomic and phosphoproteomic analyses of phage JSS1 or JSS1Δ004 infected Salmonella strains. AD032TQ is proteomes of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AD032TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AE065TQ is proteomes of phage JSS1 or JSS1Δ004 infected CX1, a S. enterica serovar Cerro 87 dndFGH deficient strain, harboring a plasmid expressing DndFGH from Escherichia coli B7A. AE065TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected CX1 harboring a plasmid expressing DndFGH from E. coli B7A.
2024-10-04 | PXD056217 | Pride
Project description:This project is about the proteomic and phosphoproteomic analyses of phage JSS1 or JSS1Δ004 infected Salmonella strains. AD032TQ is proteomes of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AD032TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AE065TQ is proteomes of phage JSS1 or JSS1Δ004 infected CX1, a S. enterica serovar Cerro 87 dndFGH deficient strain, harboring a plasmid expressing DndFGH from Escherichia coli B7A. AE065TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected CX1 harboring a plasmid expressing DndFGH from E. coli B7A.
2024-10-04 | PXD056225 | Pride
Project description:This project is about the proteomic and phosphoproteomic analyses of phage JSS1 or JSS1Δ004 infected Salmonella strains. AD032TQ is proteomes of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AD032TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected S. enterica serovar Cerro 87. AE065TQ is proteomes of phage JSS1 or JSS1Δ004 infected CX1, a S. enterica serovar Cerro 87 dndFGH deficient strain, harboring a plasmid expressing DndFGH from Escherichia coli B7A. AE065TPST is phosphoproteome of phage JSS1 or JSS1Δ004 infected CX1 harboring a plasmid expressing DndFGH from E. coli B7A.
2024-10-04 | PXD056223 | Pride
Project description:Escherichia fergusonii harboring blaNDM-5
| PRJNA1145988 | ENA
Project description:Background: It remains unclear how high-risk Escherichia coli lineages, like sequence type (ST) 131, initially adapt to carbapenem exposure in its progression to becoming carbapenem resistant. Methods: Carbapenem mutation frequency was measured in multiple subclades of extended-spectrum β-lactamase (ESBL) positive ST131 clinical isolates using a fluctuation assay followed by whole genome sequencing (WGS) characterization. Genomic, transcriptomic, and porin analyses of ST131 C2/H30Rx isolate, MB1860, under prolonged, increasing carbapenem exposure was performed using two distinct experimental evolutionary platforms to measure fast vs. slow adaptation. Results: All thirteen ESBL positive ST131 strains selected from a diverse (n=184) ST131 bacteremia cohort had detectable ertapenem (ETP) mutational frequencies with a statistically positive correlation between initial ESBL gene copy number and mutation frequency (r = 0.87, P<1e-5). WGS analysis of mutants showed initial response to ETP exposure resulted in significant increases in ESBL gene copy numbers or mutations in outer membrane porin (Omp) encoding genes in the absence of ESBL gene amplification with subclade specific adaptations. In both experimental evolutionary platforms, MB1860 responded to initial ETP exposure by increasing blaCTX-M-15 copy numbers via modular, insertion sequence 26 (IS26) mediated pseudocompound transposons (PCTns). Transposase activity driven by PCTn upregulation was a conserved expression signal in both experimental evolutionary platforms. Stable mutations in Omp encoding genes were detected only after prolonged increasing carbapenem exposure consistent with clinical observations. Conclusions: ESBL gene amplification is a conserved response to initial carbapenem exposure, especially within the high-risk ST131 C2 subclade. Targeting such amplification could assist with mitigating carbapenem resistance development.
2024-08-04 | GSE273456 | GEO